November 6, 2018

To: **Interested Parties**
From: **Anzalone Liszt Grove Research**
Re: **Pre-election polling in TX-32**

Polling conducted just days before the midterm election finds the congressional race in Texas' 32nd congressional district is dead-even.

Regardless of the election's outcome, it is clear that the closeness of this race is attributable in some part to paid communication tying Congressman Sessions to the pharmaceutical industry and demonstrating the ways in which he put pharmaceutical companies ahead of people.

The following are key findings based on polling conducted on behalf of Patients for Affordable Prescription Drugs Action (P4AD Action) in August and again in November in TX-32. For full methodology, refer to appendix A.

<u>**Key Findings**</u>

1. **Drug corporations are unpopular in Texas.** "Big Pharma" is underwater by 34% in the 32nd District of Texas. In fact, 61% of voters are more favorable toward Allred because he refused to accept any contributions from pharmaceutical companies. 53% of voters in the district believe rising prescription drug prices are a "major concern".

2. **Voters fault Congress as well as the drug companies for increased prescription prices.** More than two-thirds of voters (68%) believe that drug companies jack up prescription prices to increase their profits, a 14-point increase since the summer. Voters are now also more likely to believe that drug prices are so high because drug companies spend millions contributing to congressional campaigns (45%, up from 35% over the summer).

3. **Voters recall seeing ads tying Congressman Sessions to the pharmaceutical industry.** More than half (55%) of voters have seen ads (online or TV) or received mail about the money Sessions has taken from drug companies, or the votes he has taken to benefit the industry. Beyond this, two-thirds (63%) report having seen a lot or some information about Session's views on health care and prescription drug prices in the weeks leading up to the election.

4. **Over the course of P4AD Action's paid communication campaign against Sessions, his unfavorable rating increased nine points.** At the end of the summer, Congressman Sessions' popularity was 44% favorable / 35% unfavorable. In our pre-election polling, his unfavorable rating had increased nine points, and his favorable rating had not improved (44% favorable / 46% unfavorable).

5. **Voters became more likely to believe Sessions is "in the pocket of drug companies", and not "working to reduce prescription drug prices."** In our benchmark, voters did not believe that Sessions was in the pocket of drug company lobbyists (35% did not believe it described him well / 28% believe it described him well). However, by the end of the P4AD Action campaign, voters were divided, 35% well / 37% not well, a net five point gain.

Over the summer, voters narrowly believed Sessions was working to reduce prescription drug prices (30% well / 27% not well), but in our pre-election track, voters shifted a net nine points the other direction, (39% NOT well / 32% well).

Appendix A: Methodology

Anzalone Liszt Grove Research conducted two polls on behalf of Patients for Affordable Drugs Action in TX-32.

The first poll was conducted August 27-31, 2018 among N=500 likely general election voters. The second poll was conducted November 1-4, 2018. Interviews in both surveys were conducted via landline and cell phone by live interviewers. The results are subject to a margin of error of 4.4 points.